Strengths and Gaps in the Canadian Vaccine Landscape: a biotech perspective Nathalie Charland, PhD Sr. Director, Scientific liaisons Vaccine Innovation Conference May 26, 2015

© Medicago Inc. All rights reserved 2 ® Numerous strengths in the Canadian vaccine industry: –Strong tradition of entrepreneurial spirit –Academic excellence –Rich history of innovation –Competitive costs –Accessible market BUT innovative vaccine candidates often left on a shelf or developed outside Canada One of the principal reasons why biotech companies struggle to bring a product to market: “Collaboration Gap” –Translation of academic ideas into practical realities –GMP financing –Contacts –Flexibility re: opportunities Canadian Vaccine Industry: attractive innovation but…

© Medicago Inc. All rights reserved 3 ® A specialized industry –Relatively small (4% of pharma) but very dynamic –Interaction with Governments more important than in other markets Similar challenges –Capital intensive –High risk and long timelines –Financing (Canadian vs. US stock market) Need to build collaborative models –Multiple partners: Biotech/Pharmas, Public/Private, Not-for-Profit –Big Pharmas playing a more and more important role for smaller companies for vaccine pipeline development The challenge of vaccines for biotechs

© Medicago Inc. All rights reserved 4 ® One of the few biotech companies that has succeeded in its growth process while remaining in Canada About 300 employees; labs and collaborations around the world Succeeded in bringing a Canadian innovation out of the laboratory Attracted international investments –$245M investment to build a production facility in Quebec City –Creation of 200 new high-skilled jobs by 2019 Proceeding to the market at pace, allowing Canada to a return on of its investment Medicago’s example

© Medicago Inc. All rights reserved 5 ® Strengths: –Build on them Weaknesses –Collaborate Opportunities –Not all opportunities are equal Threats –Opportunities could be threats! Know your strengths & weaknesses, choose your opportunities, identify threats

© Medicago Inc. All rights reserved 6 ®  Founded in 1999 (licensed out from ULaval & Agriculture Canada)  2003: new CEO  Business model revision  From service provider to manufacturer of innovative products  Versatile platform with a vaccine focus  Access to highly qualified people  Breakthrough: –Discovery of plant-made virus-like particles Medicago: a Canadian success story

© Medicago Inc. All rights reserved 7 ® different patented technologies (patent families) Protected by 625 patents (granted and pending) Technologies protected in 48 countries Medicago patent portofolio

© Medicago Inc. All rights reserved 8 ® Gouvernments & agencies Key elements to success – Partnerships

© Medicago Inc. All rights reserved 9 ® Universities & colleges Key elements to success – Partnerships Biotech companies or biopharma & research organizations

© Medicago Inc. All rights reserved 10 ®  Focus –SWOT analysis (Strengths, Weaknesses, Opportunities, Threats)  Protect IP –Your bread & butter  Partnerships: –Collaborate early –Collaborate often –Be creative, opportunisitic in your collaborations! Lessons learned by Medicago

Merci! Thank you! Arigatō!